Maze Therapeutics [MAZE] vs Regeneron [REGN] Detailed Stock Comparison

Maze Therapeutics Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Maze Therapeutics Inc. wins in 2 metrics, Regeneron Pharmaceuticals, Inc. wins in 12 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Maze Therapeutics Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) 189.50 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio 3.68 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 6.57 9.51 Maze Therapeutics Inc.
PEG Ratio -5.25 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -7.11 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) 0.00% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) 0.00% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -47.52% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -28.01% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-112.73M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 164.34% 25.39% Maze Therapeutics Inc.
Price-to-Sales Ratio (TTM) N/A 5.50 N/A
Enterprise Value $998.67M $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio N/A 4.95 N/A
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) N/A $137 N/A
Earnings per Share (Diluted) $-3.05 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) N/A 0.40 N/A
Short % of Float 9.32% 2.55% Regeneron Pharmaceuticals, Inc.

Maze Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

MAZE
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Maze Therapeutics Inc.2.35%-4.57%-7.69%-43.73%-40.08%-37.49%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Maze Therapeutics Inc.164.34%65.89%65.89%65.89%65.89%65.89%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Maze Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricMAZEREGN
Market Information
Market Cap i$1.29B$80.98B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i1,174,955642,495
90 Day Avg. Volume i1,253,272617,765
Last Close$24.86$618.95
52 Week Range$9.83 - $53.65$476.49 - $821.11
% from 52W High-53.66%-24.62%
All-Time High$53.65 (Mar 16, 2026)$1,211.20 (Aug 26, 2024)
% from All-Time High-53.66%-48.90%
Growth Metrics
Quarterly Revenue GrowthN/A0.03%
Quarterly Earnings GrowthN/A-0.08%
Financial Health
Profit Margin (TTM) i0.00%0.31%
Operating Margin (TTM) i0.00%0.23%
Return on Equity (TTM) i-0.48%0.15%
Debt to Equity (MRQ) i6.579.51
Cash & Liquidity
Book Value per Share (MRQ)$7.20$304.65
Cash per Share (MRQ)$6.88$83.86
Operating Cash Flow (TTM) i$-111,940,000$4.98B
Levered Free Cash Flow (TTM) i$-72,523,872$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Maze Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricMAZE (Apr 24, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i189.5018.00
Forward P/E i-7.6114.21
PEG Ratio i-5.25-4.80
Price to Sales (TTM) iN/A5.50
Price to Book (MRQ) i3.682.45
Market Capitalization
Market Capitalization i$1.29B$80.98B
Enterprise Value i$998.67M$70.98B
Enterprise Value Metrics
Enterprise to Revenue iN/A4.95
Enterprise to EBITDA i-7.1116.72
Risk & Other Metrics
Beta iN/A0.40
Book Value per Share (MRQ) i$7.20$304.65

Financial Statements Comparison: Maze Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMAZE (2025)REGN (2025)
Revenue/Sales i014.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i-14.6%
Gross Profit iN/A12.24B
Gross Margin i-85.4%
Research & Development i108.45M5.85B
Operating Income (EBIT) i-142.90M3.70B
Operating Margin i-25.8%
EBITDA i-140.50M5.00B
EBITDA Margin i-34.8%
Pre-Tax Income i-131.12M5.23B
Pre-Tax Income % of Revenue i-36.5%
Income Tax i0725.80M
Income Tax % of Revenue i-5.1%
Net Income (Profit) i-131.12M4.50B
Profit Margin i-31.4%

Balance Sheet & Liquidity Metrics

MetricMAZE (2025)REGN (2025)
Cash & Equivalents i189.25M3.12B
Total Current Assets i349.72M18.02B
Total Current Assets % of Revenue i-125.7%
Total Current Liabilities i22.56M4.37B
Total Current Liabilities % of Revenue i-30.5%
Long-Term Debt i18.51M2.71B
Long-Term Debt % of Revenue i-18.9%
Total Shareholders Equity i354.97M31.26B
Retained Earnings i-489.55M35.80B
Retained Earnings % of Revenue i-249.6%
Property, Plant & Equipment i36.07M1.54B

Cash Flow Statement Comparison

MetricMAZE (2025)REGN (2025)
Operating Cash Flow i-112.48M6.30B
Operating Cash Flow % of Revenue i-43.9%
Capital Expenditures i-794,0000
Free Cash Flow i-112.73M3.77B
FCF Margin i-26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricMAZEREGN
Shares Short i3.89M2.55M
Short Ratio i3.354.46
Short % of Float i9.32%2.55%
Shares Outstanding i49.34M105.72M
Float Shares i27.70M98.55M
% Held by Insiders i1.65%1.98%
% Held by Institutions i93.39%91.08%
% Held by Public i4.96%6.94%

Dividend Analysis & Yield Comparison: Maze Therapeutics Inc. vs Regeneron Pharmaceuticals, Inc.

MetricMAZEREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026